Pharmacy & Biological Sciences
Category
After 15 Years of Failure, What Can Pharma Offer Alzheimer’s Patients?
The most recent new treatment for Alzheimer’s disease was approved by European regulators in May 2002, with the US FDA following suit the next year.
Top 10 U.S. Biopharma Clusters
All 10 regions ranked have significant assets that make them attractive to biopharma researchers, executives, and investors.
Are Pharmaceutical Companies to Blame for the Opioid Epidemic?
Recent lawsuits are asking courts whether the current crisis is comparable to the one over tobacco in the ’90s.
Texas on Track to Become First State to Explicitly Back Stem Cell Therapies
For years, clinics across the country have been offering experimental stem cell therapies, but no state has given them legal validation—yet.
New FDA Commissioner Gottlieb Unveils Price-fighting Strategies
The FDA can’t regulate drug prices, but it can implement measures aimed at deterring the types of price hikes that have made so many headlines over more than a year.
Taxing Drug Price Spikes: Assessing the Potential Impact
How a proposed tax penalty on drugs with price increases exceeding the inflation could impact patients, public insurance programs, and innovation.
As Trump Pressures FDA for Faster Drug Approvals, Major Safety Issues with Past Approvals Surface
Researchers found nearly a third of approvals from 2001 through 2010 had major safety issues years after they were widely available to patients.
How Pharmacists Can Lead an Opioid Exit Plan
Managing post-op pain is a team effort—and who better to lead the team than a medication expert?
FDA Clears New ALS Drug for US Market
The arrival of Radicava for ALS marks the first new drug in the market for this rare disease since 1995.
Congress Defies Trump, Gives Big Raise to NIH Medical Research
Congress grants the National Institutes of Health a $2 billion raise.